Skip to main content

Advertisement

SpringerLink
Log in

Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus

  • Published:
Surgical Endoscopy Aims and scope Submit manuscript

Abstract

Background

Endoscopic endoluminal radiofrequency ablation is achieving increasing acceptance as a mode of eliminating Barrett’s metaplasia and, thus, reducing the risk of developing esophageal adenocarcinoma. It is believed that reducing exposure of the esophageal epithelium to acid is essential to achieve long-term ablation of Barrett’s esophagus. However, it is unclear whether use of proton pump inhibitors or antireflux operations are more effective to accomplish this goal.

Methods

All patients who underwent endoscopic endoluminal radiofrequency ablation with the BARRx device (BARRx Medical, Sunnyvale, CA) were reviewed for date of initial ablation, length of Barrett’s epithelium, presence or performance of Nissen fundoplication, all follow-up endoscopy and treatment, and posttreatment biopsy results. Patients were categorized by presence of Nissen fundoplication and presence of Barrett’s metaplasia or dysplasia by biopsy at least 12 months following ablation and at last endoscopic follow-up. Data were analyzed by Fisher’s exact test and Mann–Whitney U-test.

Results

Of 77 patients ablated, 47 had documented endoscopic follow-up at 12 months or longer following the ablation. Of these, 19 patients had Nissen fundoplication before, at the same time, or after ablation. Median length of Barrett’s epithelium, with interquartile range (IQR), was 3 (2–12) cm in patients with fundoplication compared with 3 (2–7) cm without fundoplication (P = NS). Median follow-up was 15 (12–24) months in fundoplication patients compared with 12.5 (12–17) months without (P = NS). One of 19 patients with fundoplication had persistent or recurrent Barrett’s epithelium, compared with 7 of 28 without fundoplication (P = 0.03). Of patients without fundoplication, those who had persistent or recurrent Barrett’s had median Barrett’s length of 10 cm (6–12 cm) compared with 3 cm (2–5 cm) in patients who had ablated Barrett’s (P = 0.03). Follow-up length was similar in those with ablated epithelium, 15 months (12–19 months), compared with those with persistent or recurrent Barrett’s, 12 months (12–13 months) (P = NS).

Conclusions

Patients who had fundoplication in conjunction with endoluminal radiofrequency ablation were more likely to achieve durable ablation compared with patients who were treated with proton pump inhibitor therapy. It appears that patients with long-segment Barrett’s esophagus are at higher risk for persistent or recurrent Barrett’s metaplasia. Consideration should be given for an antireflux operation in patients with long-segment Barrett’s esophagus and planned endoluminal radiofrequency ablation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hamilton SR, Smith RR, Cameroon JL (1988) Prevalence and characteristics of Barrett’s esophagus in patients with adenocarcinoma of the esophagus or esophagogastric juction. Hum Pathol 19:942–948

    Article  PubMed  CAS  Google Scholar 

  2. Drewitz DJ, Sampliner RE, Garewal HS (1997) The incidence of adenocarcinoma in Barrett’s esophagus; a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 92:212–215

    PubMed  CAS  Google Scholar 

  3. Spechler SJ (2002) Barrett’s esophagus. N Engl J Med 346:836–842

    Article  PubMed  Google Scholar 

  4. Shaheen NJ, Richter JE (2009) Barrett’s oesophagus. Lancet 373:850–861

    Article  PubMed  CAS  Google Scholar 

  5. Vaezi MF, Richter JE (1996) Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 111:1192–1199

    Article  PubMed  CAS  Google Scholar 

  6. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE (2006) Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 4:566–572

    Article  PubMed  Google Scholar 

  7. Sharma VK, Wang KK, Overholt BF et al (2007) Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients. Gastrointest Endoc 65:185–195

    Article  Google Scholar 

  8. Ganz RA, Overholt BF, Sharma VK et al (2008) Circumferential ablation of multicenter registry. Gastrointest Endosc 68:35–40

    Article  PubMed  Google Scholar 

  9. Shaheen NJ, Sharma P, Overholt BF et al (2009) Radiofrequency Ablation in Barrett’s Esophagus with Dysplasia. NEJM 360:2277–2288

    Article  PubMed  CAS  Google Scholar 

  10. Velanovich V (2009) Endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus: initial results and lessons learned. Surg Endosc 23:2175–2180

    Article  PubMed  Google Scholar 

  11. Rees JRE, Lao-Sirieix P, Wong A, Fitzgerald RC (2010) Treatment for Barrett’s oesophagus (review). Cochrane Collaboration 1:1–32

    Google Scholar 

  12. Paulson T, Xu LJ, Sanchez CA et al (2006) Neosquamous epithelium does not typically arise from Barrett’s epithelium. Clin Cancer Res 12:1701–1706

    Article  PubMed  CAS  Google Scholar 

  13. Fleischer DE, Overholt BF, Sharma VK et al (2008) Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endoc 68:867–876

    Article  Google Scholar 

  14. Hubbard N, Velanovich V (2007) Endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus in patients with fundoplications. Surg Endosc 21:625–628

    Article  PubMed  CAS  Google Scholar 

  15. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE (2004) Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol 99:1877–1883

    Article  PubMed  CAS  Google Scholar 

  16. Bammer T, Hinder RA, Klause A et al (2001) Rationale for surgical therapy of Barrett Esophagus. Mayo Clin Proc 76:335–342

    Article  PubMed  CAS  Google Scholar 

  17. StataCorp (2003) Stata statistical software: release 8.0. Stata Corportation, College Station, TX

    Google Scholar 

  18. Shaheen NJ, Crosby MA, Bozymski EM et al (2000) Is there a publication bias in reporting cancer risk in Barrett’s esophagus? Gastroenterology 119:333–338

    Article  PubMed  CAS  Google Scholar 

  19. O’Connor JB, Falk GW, Richter JE (1999) The incidence of adenocarcinoma and dysplasia in Barrett’s esophagus: report on the Cleveland Clinic Barrett’s Esophagus Registry. Am J Gastroenterol 94:2037–2042

    PubMed  Google Scholar 

  20. Schnell TG, Sontag SJ, Chejfec G et al (2001) Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology 120:1607–1619

    Article  PubMed  CAS  Google Scholar 

  21. Robertson CS, Mayberry JF, Nicholson DA et al (1988) Value of endoscopic surveillance in the detection of neoplastic change in Barrett’s oesophagus. Br J Surg 75:760–763

    Article  PubMed  CAS  Google Scholar 

  22. Williamson WA, Ellis FH Jr, Gibb SP et al (1991) Barret’s esophagus: prevalence and incidence of adenocarcinoma. Arch Intern Med 151:2212–2216

    Article  PubMed  CAS  Google Scholar 

  23. Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB (2003) Temporal trends (1973–1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 98:1627–1633

    PubMed  Google Scholar 

  24. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G (2004) Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett’s oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 20:637–643

    Article  PubMed  CAS  Google Scholar 

  25. Ouatu-Lascar R, Triadafilopoulos G (1998) Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett’s esophagus. Am J Gastroenterol 93:711–716

    Article  PubMed  CAS  Google Scholar 

  26. Vacchani A, Olds G, Velanovich V (2009) Esomeprazole—a proton pump inhibitor. Exp Rev Gastroenterol Hepatol 3:15–27

    Article  Google Scholar 

  27. Dvorak K, Payne CM, Chavarria M et al (2007) Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett’s oesophagus. Gut 56:763–771

    Article  PubMed  CAS  Google Scholar 

  28. Vaezi MF, Richter JE (1995) Synergism of acid and duodenogastroesophageal reflux in complicated Barrett’s esophagus. Surgery 117:699–704

    Article  PubMed  CAS  Google Scholar 

  29. Theisen J, Peters JH, Stein HJ (2003) Experimental evidence for mutagenic potential of duodenogastric juice on Barrett’s esophagus. World J Surg 27:1018–1020

    Article  PubMed  Google Scholar 

  30. Jolly AJ, Wild CP, Hardie LJ (2004) Acid and bile salts induce DNA damage in human oesophageal cell lines. Mutagenesis 19:319–324

    Article  PubMed  CAS  Google Scholar 

  31. Castell DO, Richter JE, Robinson M et al (1996) Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 91:1749–1757

    PubMed  CAS  Google Scholar 

  32. Spechler SJ (2000) Medical treatment of Barrett’s esophagus. J Gastrointest Surg 4:119–121

    Article  PubMed  CAS  Google Scholar 

  33. Sarela AI, Hick DG, Verbeke CS et al (2004) Persistent acid and bile reflux in asymptomatic patients with Barrett’s esophagus receiving proton pump inhibitors. Arch Surg 139:547–551

    Article  PubMed  CAS  Google Scholar 

  34. Mann NS, Tsai MF, Nair PK (1989) Barrett’s esophagus in patients with symptomatic reflux esophagitis. Am J Gastroenterol 84:1494–1496

    PubMed  CAS  Google Scholar 

  35. Cameron AJ (1999) Barrett’s esophagus: Prevalence and size of hiatal hernia. Am J Gastroenterol 94:2054–2059

    Article  PubMed  CAS  Google Scholar 

  36. Stein HF, Kauer WK, Feussner H et al (1998) Bile reflux in benign and malignant Barrett’s esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg 2:333–341

    Article  PubMed  CAS  Google Scholar 

  37. Iftikhar SY, James PD, Steele RJ et al (1992) Length of Barrett’s oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 33:1155–1158

    Article  PubMed  CAS  Google Scholar 

  38. Van der Burgh A, Dees J, Hop QC et al (1996) Oesophageal cancer is an uncommon cause of death in patients with Barrett’s oesophagus. Gut 39:5–8

    Article  PubMed  Google Scholar 

  39. Weston AP, Krmpotich PT, Cherian R et al (1997) Prospective long-term endoscopic and histological follow-up of short segment Barrett’s Esophagus: comparison with traditional long segment Barrett’s Esophagus. Am J Gastroenterol 92:407–413

    PubMed  CAS  Google Scholar 

  40. Fitzgerald RC, Omary MB, Triadafilopoulos G (1996) Dynamic effects of acid on Barrett’s esophagus; an ex vivo proliferation and differentiation model. J Clin Invest 98:2120–2128

    Article  PubMed  CAS  Google Scholar 

  41. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ (2002) Hiatal hernia and acid reflux frequency predict presence and length of Barrett’s esophagus. Dig Dis Sci 47:256–264

    Article  PubMed  Google Scholar 

Download references

Disclosures

Kathleen O’Connell and Vic Velanovich have no conflicts of interest or financial ties to disclose.

Author information

Authors and Affiliations

  1. Division of General Surgery, K-8, Henry Ford Hospital, 2799 West Grand Blvd, Detroit, MI, 48202, USA

    Kathleen O’Connell & Vic Velanovich

Authors
  1. Kathleen O’Connell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vic Velanovich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vic Velanovich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Connell, K., Velanovich, V. Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus. Surg Endosc 25, 830–834 (2011). https://doi.org/10.1007/s00464-010-1270-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00464-010-1270-0

Keywords

Search

Navigation